Dbs denied as duplicate or overlapping therapy by Blue Cross Blue Shield?
If two medications appear duplicative on paper but serve different clinical purposes (e.g., short-acting vs long-acting), the appeal needs to spell out the clinical rationale for both.
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What Blue Cross Blue Shield typically requires
Bronstein 2011 criteria: >=4yr PD, levodopa-responsive, motor fluctuations/dyskinesia refractory to optimized medical therapy. Multidisciplinary eval (neurology + neurosurgery + neuropsych).
What works in the appeal
Submit complete multidisciplinary eval packet (Bronstein 2011 criteria documentation). Document optimized medical therapy trial (drug list + dose + duration). MoCA/MMSE within DBS-eligible range. Cite AAN PD Guidelines + MDS evidence review.
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →Related appeal guides
- Blue Cross Blue Shield denied as duplicate or overlapping therapy of 17ohp_compounded
- Blue Cross Blue Shield denied as duplicate or overlapping therapy of IVF
- Blue Cross Blue Shield denied as duplicate or overlapping therapy of Aat_augmentation
- Blue Cross Blue Shield denied as duplicate or overlapping therapy of Amphetamine_stimulant_prodrug